Effects of Helicobacter pylori eradication among adults with intellectual disability.
Killing H. pylori does not improve behaviour or daily skills in adults with ID.
01Research in Context
What this study did
Doctors gave adults with intellectual disability the normal three-drug plan to kill stomach bug H. pylori.
They checked behaviour and daily-living skills before and after treatment.
What they found
The drugs cleared the bug in 6 out of 10 people.
No one got better at self-care or showed fewer behaviour problems.
How this fits with other research
Mouridsen et al. (2013) tracked adults with atypical autism for 33 years and found no extra gut disease. This clashes with the idea that hidden GI trouble drives behaviour problems.
Matson et al. (2009) also tried a gut drug—oral immunoglobulin—in autistic children and saw no gains, matching the null result here.
McHugh et al. (2023) show that teaching adults to manage their own behaviour cuts problem acts, pointing to skill-building, not pills, as the useful path.
Why it matters
Stop hunting for hidden stomach bugs to explain challenging behaviour in adults with ID. If H. pylori shows up on a medical test, treat it for health reasons, but do not expect calmer days or better self-help skills. Spend your effort on behavioural or self-management plans that have real data behind them.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Keep behaviour plans in place when an adult with ID tests positive for H. pylori—do not expect the antibiotic course to cut problem behaviour.
02At a glance
03Original abstract
BACKGROUND: Compared to the general population, Helicobacter pylori infection is more common among adults with intellectual disability (ID) and is associated with greater levels of disability, maladaptive behaviour, and institutionalization. Little information exists about the effects of eradication therapy in this group, so we aimed to evaluate: (1) success of a standard H. pylori eradication protocol; (2) frequency of side-effects; and (3) impact of eradication on level of functional ability and maladaptive behaviour. METHOD: A cohort of adults with ID underwent assessment of their levels of function and maladaptive behaviour, medical history, physical examination, and H. pylori testing using serology and faecal antigen tests. Some received standard H. pylori eradication therapy. Twelve months later, participants underwent repeat assessment, were grouped by change in H. pylori status and compared. RESULTS: Of 168 participants, 117 (70%) were currently infected with H. pylori at baseline, and 96 (82%) of the 117 were given standard H. pylori eradication therapy. The overall eradication rate was 61% but 31% reported side-effects. Institutional status of the participants, their level of behaviour or function, and number of comorbid medical conditions were not associated with failure of eradication. There were no statistically significant differences in level of behaviour or function, ferritin, or weight between the groups in whom H. pylori was eradicated or stayed positive. CONCLUSION: Adults with ID have lower H. pylori eradication and higher side-effect rates than the general population. Levels of maladaptive behaviour and disability did not improve with eradication and thus greater levels of maladaptive behaviour or disability appear to be risk factors for, rather than consequences of, H. pylori infection.
Journal of intellectual disability research : JIDR, 2004 · doi:10.1111/j.1365-2788.2003.00560.x